Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT1: Definity LVEF Accuracy Study
NCT03571672Phase 3Completed
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of perflutren lipid microspheres in heart disease, sponsored by Lantheus Holdings, Inc. Primary endpoint: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader at 30 days. Started Oct 2018; status: completed.
02
Drugs
perflutren lipid microspheres
03
Conditions
heart disease
Beyond the preview
Go deeper on NCT03571672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571672.